Olaparib approved for 800 prostate and breast cancer patients in England
Who is olaparib now recommended for?
- HER2-negative breast cancer patients with high-risk, early-stage disease, after chemotherapy and surgery. This group includes people with hormone receptor-positive and triple-negative breast cancer.
- Prostate cancer patients whose disease has spread through their body (metastasized), and either returned or grown bigger after being treated with hormone therapy.
How does olaparib work?
How were PARP inhibitors discovered?
Source: Read Full Article